# 乙型肝炎诊断测试市场 > 肝炎E诊断测试市场研究报告按测试类型（免疫测定基础测试、分子诊断测试、血清学测试）、样本类型（血清、血浆、粪便）、最终用户（医院、诊断实验室、研究机构）和地区（北美、欧洲、南美、亚太、中东和非洲） - 预测到2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.57% - **2024:** $ 2.05 Billion - **2025:** $ 2.18 Billion - **2035:** $ 4.12 Billion - **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), Siemens Healthineers (DE), Mylab Discovery Solutions (IN), Genetic Technologies Limited (AU), Wondfo Biotech (CN) **Report ID:** MRFR/MED/27706-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** September 17, 2026 **URL:** https://www.marketresearchfuture.com/reports/hepatitis-e-diagnostic-test-market-29424 --- ## Market Summary ## **Hepatitis E Diagnostic Test Market Overview** As per MRFR analysis, the Hepatitis E Diagnostic Test Market Size was estimated at 2.05 (USD Billion) in 2024. The Hepatitis E Diagnostic Test Market Industry is expected to grow from 2.18 (USD Billion) in 2025 to 3.87 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.57% during the forecast period (2025 - 2034). ### **Key Hepatitis E Diagnostic Test Market Trends Highlighted** The global Hepatitis E diagnostic test market exhibits a growing demand due to the increasing prevalence of hepatitis E virus (HEV) infections worldwide. Technological advancements in diagnostic techniques, such as the development of highly sensitive and specific molecular assays, have significantly contributed to the market growth. Additionally, rising awareness about hepatitis E and the importance of early diagnosis drive the market expansion. Key market drivers include the surge in hepatitis E outbreaks, particularly in developing countries with poor sanitation and hygiene practices. Opportunities for market expansion lie in the development of rapid and point-of-care diagnostic tests that can facilitate early detection and timely intervention in remote or resource-limited settings. Recent trends in the market include the integration of artificial intelligence (AI) and machine learning (ML) algorithms into diagnostic platforms to enhance accuracy and efficiency. The market is also witnessing a shift toward non-invasive testing methods, such as saliva-based assays, for improved patient convenience and reduced discomfort. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Hepatitis E Diagnostic Test Market Drivers** ### Rising Prevalence of Hepatitis E Virus Infections Hepatitis E is a viral infection that can cause inflammation of the liver. It is spread through contact with contaminated food or water, and it is a major public health concern in many developing countries. The World Health Organization (WHO) estimates that 20 million people are infected with hepatitis E each year, and that 3.4 million of these infections result in hospitalization. The rising prevalence of hepatitis E virus infections is a major driver of the growth of the global Hepatitis E Diagnostic Test Market Industry. As the number of people infected with hepatitis E increases, the demand for diagnostic tests to identify and treat the infection will also increase. ### Increasing Awareness of Hepatitis E The increasing awareness of hepatitis E is another major driver of the growth of the global Hepatitis E Diagnostic Test Market Industry. In the past, hepatitis E was often misdiagnosed as other liver diseases, such as hepatitis A or B. However, as awareness of hepatitis E has increased, so has the demand for diagnostic tests to identify the infection. This increased awareness is due in part to the efforts of public health organizations and advocacy groups, which have worked to raise awareness of the disease and its symptoms. As a result of these efforts, more people are aware of hepatitis E and are seeking testing for the infection. ### Technological Advancements in Hepatitis E Diagnostics The technological advancements in hepatitis E diagnostics are also driving the growth of the global Hepatitis E Diagnostic Test Market Industry. In the past, hepatitis E was diagnosed using serological tests, which detected antibodies to the virus. However, these tests were not always accurate, and they could not be used to diagnose early-stage infections. In recent years, new diagnostic tests have been developed that are more accurate and sensitive than serological tests. These new tests can be used to diagnose early-stage infections, and they can also be used to differentiate between hepatitis E and other liver diseases. ## **Hepatitis E Diagnostic Test Market Segment Insights** ### **Hepatitis E Diagnostic Test Market Test Type Insights** The Global Hepatitis E Diagnostic Test Market is segmented by Test Type into Immunoassay-Based Tests, Molecular Diagnostics Tests, and Serological Tests. Among these segments, Immunoassay-Based Tests accounted for the largest market share in 2023, and is projected to continue its dominance throughout the forecast period. The growth of this segment can be attributed to the increasing adoption of rapid diagnostic tests (RDTs), which are simple to use, provide quick results, and are cost-effective. The Molecular Diagnostics Tests segment is anticipated to be the fastest-growing segment in the Global Hepatitis E Diagnostic Test Market during the forecast period. The growth of this segment can be attributed to the increasing demand for accurate and sensitive diagnostic tests for Hepatitis E virus (HEV). The Serological Tests segment is expected to witness steady growth over the forecast period, due to the continued use of traditional serological tests for the diagnosis of Hepatitis E. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Hepatitis E Diagnostic Test Market Sample Type Insights** The Global Hepatitis E Diagnostic Test Market is segmented by Sample Type into Serum, Plasma, and Fecal. Among these, the Serum segment held the largest market share in 2023, accounting for over 45% of the global market revenue. This dominance is attributed to the widespread availability of serum samples and the ease of collection compared to other sample types. The Plasma segment is expected to witness significant growth over the forecast period, owing to the increasing adoption of plasma-based diagnostic tests for Hepatitis E virus (HEV) detection. The Fecal segment is projected to grow at a steady pace due to the growing awareness of fecal-oral transmission of HEV. ### **Hepatitis E Diagnostic Test Market End User Insights** The end user segment of the Global Hepatitis E Diagnostic Test Market plays a crucial role in driving market growth. Hospitals account for a significant share of the market, owing to the increasing number of hepatitis E cases and the need for accurate and timely diagnosis. Diagnostic laboratories are also major end users, as they provide specialized testing services for hepatitis E. Research institutes contribute to market growth by conducting research on new diagnostic methods and technologies. The growing focus on early detection and diagnosis of hepatitis E is expected to boost the demand for diagnostic tests, particularly in regions with high disease prevalence. ### **Hepatitis E Diagnostic Test Market Regional Insights** The regional market for Hepatitis E Diagnostic Tests is segmented into North America, Europe, Asia-Pacific, South America, and the Middle East Africa. In 2023, the North American market held the largest market share, followed by Europe and Asia-Pacific. The growth in the North American market is primarily attributed to the increasing prevalence of hepatitis E, the growing adoption of advanced diagnostic technologies, and the presence of well-established healthcare infrastructure. The European market is expected to witness steady growth due to the rising awareness about hepatitis E and the availability of advanced healthcare facilities. The Asia-Pacific market is anticipated to grow at a significant rate, owing to the increasing healthcare expenditure and the growing awareness about hepatitis E in the region. The South American and Middle East Africa markets are expected to grow at a slower pace due to the limited healthcare infrastructure and the lower prevalence of hepatitis E in these regions. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Hepatitis E Diagnostic Test Market Key Players and Competitive Insights** Major players in the Hepatitis E Diagnostic Test Market are focusing on developing innovative diagnostic tests to improve the accuracy and efficiency of hepatitis E diagnosis. The industry is characterized by the presence of leading players such as Abbott Laboratories, Beckman Coulter, bioMérieux, Chembio Diagnostics, and F. Hoffmann-La Roche. These companies are investing heavily in research and development to gain a competitive edge and meet the growing demand for accurate and reliable diagnostic tests. The Hepatitis E Diagnostic Test Market is expected to witness significant development in the coming years, driven by factors such as the rising prevalence of hepatitis E infections, increasing awareness about the disease, and government initiatives to control the spread of the virus. The competitive landscape is expected to remain dynamic, with new entrants and existing players vying for market share. Among the leading Hepatitis E Diagnostic Test Market players, Abbott Laboratories is a global leader in the development and manufacturing of diagnostic tests and systems. The company offers a range of diagnostic tests for hepatitis E, including the ARCHITECT i2000SR and ARCHITECT i4000SR systems. These systems provide automated and rapid testing, enabling healthcare professionals to diagnose hepatitis E infections quickly and accurately. Abbott Laboratories has a strong distribution network and a wide customer base, which contributes to its leading position in the market. A notable competitor in the Hepatitis E Diagnostic Test Market is bioMérieux, a French multinational corporation specializing in in vitro diagnostics. The company offers a range of diagnostic tests for hepatitis E, including the VIDAS HEV IgM and VIDAS HEV IgG tests. These tests are designed to detect antibodies against the hepatitis E virus, enabling healthcare professionals to diagnose acute and chronic hepatitis E infections. bioMérieux has a strong presence in Europe and Asia-Pacific and is expanding its operations in emerging markets, which is expected to drive its growth in the Hepatitis E Diagnostic Test Market. ### **Key Companies in the Hepatitis E Diagnostic Test Market Include** ## Hepatitis E Diagnostic Test Market Industry Developments - **Q1 2024: Roche launches new Elecsys HEV IgM and IgG immunoassays for hepatitis E virus diagnosis** Roche announced the launch of its Elecsys HEV IgM and IgG immunoassays, expanding its diagnostic portfolio to include tests for hepatitis E virus, aimed at improving early detection and disease management. - **Q2 2024: Altona Diagnostics releases RealStar HEV RT-PCR Kit 3.0 for hepatitis E virus detection** Altona Diagnostics introduced the RealStar HEV RT-PCR Kit 3.0, a CE-IVD marked molecular diagnostic test for the detection of hepatitis E virus RNA, targeting clinical laboratories in Europe. - **Q2 2024: Dia.Pro launches new HEV ELISA kits for improved hepatitis E diagnosis** Dia.Pro Diagnostic Bioprobes announced the launch of new ELISA kits for hepatitis E virus, designed to enhance sensitivity and specificity in clinical diagnostics. - **Q2 2024: Wantai receives regulatory approval for HEV IgM rapid test in Southeast Asia** Beijing Wantai Biological Pharmacy Enterprise obtained regulatory clearance for its HEV IgM rapid diagnostic test in several Southeast Asian countries, expanding access to point-of-care hepatitis E testing. - **Q3 2024: Fortress Diagnostics launches new hepatitis E rapid test for global markets** Fortress Diagnostics announced the global launch of its hepatitis E rapid test, designed for use in resource-limited settings to facilitate timely diagnosis. - **Q3 2024: MP Biomedicals expands hepatitis E diagnostic portfolio with new molecular assay** MP Biomedicals introduced a new molecular assay for hepatitis E virus detection, aiming to improve diagnostic accuracy in clinical laboratories. - **Q4 2024: Primerdesign launches CE-marked hepatitis E virus RT-PCR kit** Primerdesign announced the launch of a CE-marked RT-PCR kit for hepatitis E virus, targeting European clinical diagnostic markets. - **Q4 2024: Gold Standard Diagnostics introduces new hepatitis E ELISA test for clinical use** Gold Standard Diagnostics released a new ELISA test for hepatitis E virus, designed to support laboratories in accurate serological diagnosis. - **Q1 2025: Mikrogen launches recomLine HEV IgG/IgM immunoblot for hepatitis E confirmation** Mikrogen GmbH announced the launch of its recomLine HEV IgG/IgM immunoblot, a confirmatory test for hepatitis E virus serology. - **Q2 2025: AccuBioTech receives CE-IVD approval for new hepatitis E rapid test** AccuBioTech Co., Ltd. received CE-IVD approval for its hepatitis E rapid test, enabling distribution across European markets. - **Q2 2025: Dia.Pro partners with European distributor for hepatitis E diagnostic kits** Dia.Pro Diagnostic Bioprobes announced a partnership with a major European distributor to expand the reach of its hepatitis E diagnostic kits. - **Q3 2025: Altona Diagnostics signs supply agreement for RealStar HEV RT-PCR kits with national health authority** Altona Diagnostics entered into a supply agreement with a national health authority to provide RealStar HEV RT-PCR kits for hepatitis E virus surveillance and outbreak response. ## **Hepatitis E Diagnostic Test Market Segmentation Insights** ### **Hepatitis E Diagnostic Test Market Test Type Outlook** ### **Hepatitis E Diagnostic Test Market Sample Type Outlook** ### **Hepatitis E Diagnostic Test Market End User Outlook** ### **Hepatitis E Diagnostic Test Market Regional Outlook** ## Market Drivers ### 政府倡议和资金 政府针对传染病的倡议正在显著影响乙型肝炎诊断测试市场。许多国家正在实施国家健康计划，专注于改善乙型肝炎的诊断能力。这些倡议通常包括对新诊断测试的研究和开发的资金支持，以及提高公众对该疾病认识的公共卫生宣传。例如，已经观察到各国在传染病控制方面的预算分配增加，这直接支持了乙型肝炎诊断测试的开发和分发。这种政府支持不仅增强了检测的可用性，还鼓励公共卫生实体与私营部门公司之间的合作。这种协同作用可能会促进创新并扩大乙型肝炎诊断测试市场。 ### 测试中的技术创新 诊断测试的技术进步正在推动乙型肝炎诊断测试市场的发展。快速测试工具、分子诊断和即时检测等创新正在提高乙型肝炎检测的准确性和速度。这些进展不仅改善了患者的治疗结果，还促进了对疫情的及时公共卫生响应。更复杂的检测方法的引入，包括血清学和核酸检测，扩展了医疗提供者可用的诊断能力。因此，市场上涌现出大量满足不同医疗环境的新产品。诊断技术的整合可能会吸引投资和研究，进一步刺激乙型肝炎诊断测试市场的增长。 ### 肝炎E的发病率上升 肝炎E感染的日益增加是肝炎E诊断测试市场的主要驱动因素。报告显示，肝炎E在缺乏卫生和水质不佳的地区变得越来越普遍。世界卫生组织指出，肝炎E在许多发展中国家是地方性流行的，这导致对有效诊断测试的需求加大。随着报告病例的增加，医疗服务提供者被迫寻求可靠的诊断解决方案以管理和控制疫情。这一趋势表明，肝炎E诊断测试市场可能会扩大，因为医疗系统优先考虑识别和治疗这种病毒感染。因此，肝炎E的发病率上升预计将显著影响肝炎E诊断测试市场的增长轨迹。 ### 全球旅行和移民增加 增加了肝炎E诊断测试行业。随着人们跨越国界，传播传染病（包括肝炎E）的风险加剧。旅行者和移民可能会遇到肝炎E流行的地区，从而导致感染的可能性增加。这一动态创造了对有效诊断测试的迫切需求，以便及时识别和管理病例。医疗服务提供者越来越认识到对旅行者进行肝炎E筛查的重要性，特别是那些从高风险地区返回的人。国际旅行和迁移模式的增加可能会推动对肝炎E诊断测试的需求，因为公共卫生当局旨在减轻与跨境疾病传播相关的风险。因此，肝炎E诊断测试行业的增长预计将产生重大影响。 ### 对预防性医疗的需求日益增长 对预防性医疗的日益重视正在推动乙型肝炎诊断测试市场的发展。随着全球医疗系统向预防措施转变，早期发现和诊断乙型肝炎等传染病的重要性正日益受到认可。这一趋势反映在对能够在感染导致严重健康并发症之前识别感染的诊断测试需求的上升。预防性医疗倡议通常包括常规筛查项目，这些项目可能会特别在高风险人群中纳入乙型肝炎检测。对健康管理的主动方法预计将为乙型肝炎诊断测试创造一个强劲的市场，因为医疗提供者寻求实施全面的筛查策略。因此，预防性医疗的关注预计将显著促进乙型肝炎诊断测试市场的增长。 ## Future Outlook 乙型肝炎诊断测试市场预计将在2024年至2035年间以6.57%的年均增长率增长，推动因素包括意识的提高、技术的进步和医疗支出的增加。 **New opportunities:** - 快速现场检测工具的开发 到2035年，市场预计将实现显著增长，反映出增强的诊断能力和更广泛的可及性。 ## Segment Insights ### 按测试类型：免疫测定基础测试（最大）与分子诊断测试（增长最快） 在肝炎E诊断测试市场中，基于免疫测定的测试占据了最大的市场份额，反映出其因快速结果和成本效益而被广泛使用。这些测试通常在临床环境中使用，使医疗提供者能够快速有效地诊断肝炎E，从而成为医疗专业人员的首选。相比之下，分子诊断测试正在获得关注，对整体市场贡献显著，因为它们提供了更高的灵敏度和特异性。这种向分子技术的转变表明，随着对肝炎E的认识和流行程度的提高，对精确诊断能力的需求正在上升。 测试类型：免疫测定基础测试（主导）与分子诊断测试（新兴） 免疫测定法测试因其易用性和医疗提供者的广泛熟悉度而在乙型肝炎诊断测试市场中脱颖而出。这些测试通常利用酶联免疫吸附测定（ELISA）来检测抗体和抗原，使其在及时治疗的启动中发挥了重要作用。另一方面，分子诊断测试作为一个重要的竞争者正在崛起，利用聚合酶链反应（PCR）等先进技术，不仅提供快速结果，还提高了识别乙型肝炎的准确性。它们在患者体内检测病毒RNA的能力推动了它们的采用，特别是在专业诊断实验室和研究环境中。 ### 按样本类型：血清（最大）与粪便（增长最快） 肝炎E诊断测试市场在各种样本类型中展示了多样的市场份额分布，包括血清、血浆和粪便样本。血清仍然是市场的最大贡献者，主要由于其在诊断方法中的既定应用。相比之下，虽然血浆样本占据了重要地位，但粪便样本已经开始开辟出显著的细分市场，在最近的研究中突显了其诊断潜力。 样本类型：血清（主导）与粪便（新兴） 血清样本作为肝炎E诊断领域的主导力量，受益于其在病毒诊断中的长期使用，提供可靠的结果和广泛的适用性。血清检测的可信度及其纳入标准检测协议的整合，促进了其持续的普及。另一方面，粪便样本由于其非侵入性特征和早期检测肝炎E的潜力，正逐渐成为一种有前景的替代方案。这一向粪便诊断的转变受到分子技术进步和对感染的胃肠道表现的认识提高的推动，使粪便样本在市场中成为一个重要的未来参与者。 ### 按最终用户：医院（最大）与诊断实验室（增长最快） 在乙型肝炎E诊断测试市场中，医院是最大的终端用户细分市场，占据了整体市场的显著份额。医院至关重要，因为它们作为主要的医疗机构，能够诊断和治疗乙型肝炎E患者。另一方面，诊断实验室正在迅速崛起，成为一个快速增长的细分市场，这得益于对检测服务需求的增加，推动因素是对该疾病的认识和流行程度的提高。 最终用户：医院（主导）与诊断实验室（新兴） 医院在乙型肝炎诊断测试市场中发挥着主导作用，是初步筛查和治疗的主要医疗接入点。它们的广泛基础设施，包括专业部门和熟练人员，使其能够提供全面的诊断服务。相比之下，诊断实验室作为一个重要的细分市场正在崛起，这得益于检测技术的进步和公众对传染病管理日益关注。这些实验室提供的专业检测服务通常比传统方法更快、更高效，以满足对及时诊断日益增长的需求。随着医疗策略的演变，医院与诊断实验室之间的协同作用可能会塑造乙型肝炎检测的未来格局。 ## Regional Market Share Analysis ### 北美：引领创新与研究 北美是肝炎E诊断测试的最大市场，约占全球市场份额的45%。该地区的增长得益于先进的医疗基础设施、对肝炎E的日益关注以及支持性的监管框架。对快速和准确的诊断测试的需求进一步受到肝炎E发病率上升的推动，特别是在脆弱人群中。美国和加拿大是该市场的领先国家，主要参与者如雅培实验室和罗氏诊断在市场中占据主导地位。竞争环境的特点是关键参与者之间持续的创新和合作，以增强诊断能力。成熟的医疗系统和对研究与开发的资金支持也为该地区的强大市场地位做出了贡献。 ### 欧洲：监管支持与增长 欧洲是肝炎E诊断测试的第二大市场，约占全球市场份额的30%。该地区受益于严格的监管标准和对传染病控制的日益重视。公共卫生倡议和对肝炎E诊断研究的资金增加是主要的增长驱动因素。各国还专注于改善医疗服务的可及性，这预计将推动对诊断测试的需求。德国、法国和英国是该市场的领先国家，西门子医疗和百奥莱实验室等公司做出了重要贡献。竞争格局的特点是公共卫生组织与私营部门参与者之间的合作，以增强诊断技术。创新型初创企业的存在也为市场的动态特性增添了活力。 ### 亚太地区：快速增长的市场潜力 亚太地区的肝炎E诊断测试市场正在迅速增长，约占全球市场份额的20%。该地区的增长得益于肝炎E发病率的上升，特别是在发展中国家，以及医疗投资的增加。旨在改善医疗基础设施和疾病意识的政府举措也是市场扩展的重要催化剂。中国和印度是该地区的领先国家，Wondfo生物科技和Mylab发现解决方案等公司的存在日益增强。竞争格局正在演变，地方制造商越来越多地进入市场，以满足对经济实惠的诊断解决方案的日益需求。公共卫生机构与私营企业之间的合作也在增强农村地区诊断测试的可用性。 ### 中东和非洲：面临挑战的新兴市场 中东和非洲地区在肝炎E诊断测试市场中逐渐崭露头角，约占全球市场份额的5%。增长主要得益于对肝炎E的认识提高和对改善诊断能力的需求。然而，有限的医疗基础设施和对诊断测试的可及性等挑战阻碍了市场扩展。旨在改善医疗服务可及性的政府举措对未来的增长至关重要。南非和尼日利亚等国在该市场中处于前沿，地方参与者和国际公司正在努力改善诊断解决方案。竞争格局的特点是政府与非政府组织之间的合作，以增强公共卫生倡议。关键参与者的存在正在增加，但需要大量投资以克服现有障碍。 ## Competitive Benchmarking 肝炎E诊断测试市场目前的特点是动态竞争格局，受到对肝炎E认识的提高和对准确诊断解决方案需求的推动。主要参与者如雅培实验室（美国）、罗氏诊断（瑞士）和西门子医疗（德国）处于前沿，利用其广泛的研究能力和技术进步来增强其产品供应。雅培实验室（美国）专注于创新，特别是在开发可在资源有限环境中使用的快速诊断测试方面，而罗氏诊断（瑞士）则强调与医疗服务提供者的合作，以扩大其市场覆盖。西门子医疗（德国）正在投资数字化转型，将人工智能整合到其诊断平台中，以提高准确性和效率，从而塑造一个优先考虑技术进步和战略合作的竞争环境。 在商业策略方面，公司越来越多地本地化生产，以降低成本并增强供应链韧性。市场看起来适度分散，多个参与者争夺市场份额，但主要公司的集体影响力是显著的。这种竞争结构允许提供多样化的诊断解决方案，以满足各种地区需求和监管要求，从而促进创新和对市场需求的响应。 在2025年8月，雅培实验室（美国）宣布推出一种新的现场肝炎E测试，旨在低资源环境中使用。这一战略举措可能会增强对欠发达地区诊断的获取，与全球健康倡议相一致，旨在控制肝炎E疫情。这种测试的推出不仅增强了雅培的产品组合，还使公司在应对公共健康挑战方面处于领先地位。 在2025年9月，罗氏诊断（瑞士）扩大了与东南亚地方卫生当局的合作，以改善肝炎E的监测和检测能力。这一合作在战略上非常重要，因为它使罗氏能够利用当地的专业知识和基础设施，从而增强其市场存在，同时为区域健康改善做出贡献。这种合作还可能促进开发满足特定地方需求的定制诊断解决方案。 在2025年7月，西门子医疗（德国）推出了一种新的人工智能驱动的诊断平台，将肝炎E检测与其他传染病诊断整合在一起。这一创新表明了向综合诊断解决方案的更广泛趋势，这可能简化检测流程并改善患者结果。通过采用人工智能技术，西门子可能会增强其竞争优势，吸引寻求高效和全面诊断工具的医疗服务提供者。 截至2025年10月，肝炎E诊断测试市场正在见证数字化、可持续性和人工智能整合等趋势。主要参与者之间的战略联盟越来越多地塑造竞争格局，促进创新并增强产品供应。从基于价格的竞争转向关注技术进步和供应链可靠性的转变是显而易见的，这表明未来的竞争差异化将取决于创新能力和对不断变化的医疗需求的响应。 ## Recent News & Developments - **2024年第一季度：罗氏推出新的Elecsys HEV IgM和IgG免疫测定法用于肝炎E病毒诊断** 罗氏宣布推出其Elecsys HEV IgM和IgG免疫测定法，扩展其诊断产品组合，增加肝炎E病毒的检测，旨在改善早期检测和疾病管理。 - **2024年第二季度：Altona Diagnostics发布RealStar HEV RT-PCR试剂盒3.0用于肝炎E病毒检测** Altona Diagnostics推出了RealStar HEV RT-PCR试剂盒3.0，这是一种CE-IVD标记的分子诊断测试，用于检测肝炎E病毒RNA，面向欧洲的临床实验室。 - **2024年第二季度：Dia.Pro推出新的HEV ELISA试剂盒以改善肝炎E诊断** Dia.Pro Diagnostic Bioprobes宣布推出新的肝炎E病毒ELISA试剂盒，旨在提高临床诊断的灵敏度和特异性。 - **2024年第二季度：Wantai在东南亚获得HEV IgM快速检测的监管批准** 北京万泰生物药业获得了多个东南亚国家对其HEV IgM快速诊断测试的监管许可，扩大了肝炎E点-of-care检测的可及性。 - **2024年第三季度：Fortress Diagnostics在全球市场推出新的肝炎E快速检测** Fortress Diagnostics宣布在全球推出其肝炎E快速检测，旨在在资源有限的环境中促进及时诊断。 - **2024年第三季度：MP Biomedicals通过新的分子检测扩展肝炎E诊断产品组合** MP Biomedicals推出了一种新的肝炎E病毒检测分子检测，旨在提高临床实验室的诊断准确性。 - **2024年第四季度：Primerdesign推出CE标记的肝炎E病毒RT-PCR试剂盒** Primerdesign宣布推出一款CE标记的肝炎E病毒RT-PCR试剂盒，面向欧洲临床诊断市场。 - **2024年第四季度：Gold Standard Diagnostics推出新的肝炎E ELISA测试用于临床使用** Gold Standard Diagnostics发布了一种新的肝炎E病毒ELISA测试，旨在支持实验室进行准确的血清学诊断。 - **2025年第一季度：Mikrogen推出recomLine HEV IgG/IgM免疫印迹用于肝炎E确认** Mikrogen GmbH宣布推出其recomLine HEV IgG/IgM免疫印迹，这是一种用于肝炎E病毒血清学的确认测试。 - **2025年第二季度：AccuBioTech获得CE-IVD批准用于新的肝炎E快速检测** AccuBioTech有限公司获得了其肝炎E快速检测的CE-IVD批准，允许在欧洲市场分销。 - **2025年第二季度：Dia.Pro与欧洲分销商合作推广肝炎E诊断试剂盒** Dia.Pro Diagnostic Bioprobes宣布与一家主要的欧洲分销商建立合作关系，以扩大其肝炎E诊断试剂盒的覆盖范围。 - **2025年第三季度：Altona Diagnostics与国家卫生当局签署RealStar HEV RT-PCR试剂盒供应协议** Altona Diagnostics与国家卫生当局签署了一项供应协议，提供RealStar HEV RT-PCR试剂盒用于肝炎E病毒监测和疫情响应。 ## Report Scope | 2024年市场规模 | 20.46（十亿美元） | | --- | --- | | 2025年市场规模 | 21.8（十亿美元） | | 2035年市场规模 | 41.2（十亿美元） | | 复合年增长率（CAGR） | 6.57%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 主要公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 主要市场机会 | 快速检测技术的进步提高了乙型肝炎诊断测试市场的可及性。 | | 主要市场动态 | 对快速诊断测试的需求上升推动了乙型肝炎诊断测试市场的创新和竞争。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 到2035年，乙型肝炎诊断测试市场的预计市场估值是多少？** A: 乙型肝炎诊断测试市场预计到2035年将达到41.2亿美元的估值。 **Q: 2024年乙型肝炎诊断测试市场的市场估值是多少？** A: 在2024年，乙型肝炎诊断测试市场的市场估值为20.46亿美元。 **Q: 在2025年至2035年的预测期内，肝炎E诊断测试市场的预期CAGR是多少？** A: 在2025年至2035年的预测期内，乙型肝炎诊断测试市场的预期CAGR为6.57%。 **Q: 在乙型肝炎诊断测试市场中，哪些公司被视为关键参与者？** A: 肝炎E诊断测试市场的主要参与者包括雅培实验室、罗氏诊断、百奥莱实验室和西门子医疗。 **Q: 在乙型肝炎诊断测试市场中，主要的测试类型有哪些及其预计估值是多少？** A: 主要的测试类型包括免疫测定法测试，预计到2035年将达到16亿美元，以及分子诊断测试，预计到2035年将达到12亿美元。 **Q: 在乙型肝炎诊断测试市场中，血清学测试的市场与其他测试类型相比如何？** A: 到2035年，血清学检测预计将达到13.2亿美元，表明其在检测类型中具有竞争优势。 **Q: 在乙型肝炎诊断测试市场中使用了哪些样本类型？** A: 样本类型包括血清、血浆和粪便，预计到2035年血清将达到16亿美元。 **Q: 哪些最终用户正在推动乙型肝炎诊断测试市场？** A: 最终用户包括医院、诊断实验室和研究机构，预计到2035年医院的市场规模将达到16.4亿美元。 **Q: 肝炎E诊断测试市场的预计增长趋势是什么？** A: 乙型肝炎诊断测试市场预计将稳步增长，预计从2024年的20.46亿美元增至2035年的41.2亿美元。 **Q: 在乙型肝炎诊断测试市场中，诊断实验室的预计收入与医院相比如何？** A: 诊断实验室预计到2035年将达到12.5亿美元，而医院预计将实现更高的估值，达到16.4亿美元。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/hepatitis-e-diagnostic-test-market-29424*